Meet IAG’s Musculoskeletal Expert Team at OARSI Meeting, Berlin

Meet IAG's Musculoskeletal Expert Team at OARSI Meeting, Berlin

Presenting: Towards Improving the Speed of Reporting and Reader Agreement in Knee OA Clinical Trials

Dr. Olga Kubassova, and Prof. Mikael Boesen will be attending OARSI meeting in Berlin, in person and presenting a poster ‘Towards Improving the Speed of Reporting and Reader Agreement in Knee OA Clinical Trials’, on Friday and Saturday (details below).

  • Poster Number: 608
  • Category: Clinical Aspects & Outcomes in OA
  • Onsite Category: Late Breaking
  • Poster Sessions: April 8, 3:30 PM – 5:00 PM
  • Poster Session 2: April 9, 3:30 PM – 5:00 PM

At IAG, we support our biotech and pharma partners developing novel pain targeting and disease-modifying osteoarthritis drugs. At OARSI, we will be presenting our latest work focused on improving the speed and accuracy of patient selection in clinical trials.

Precise radiological review and AI in drug development improve the trial outcomes and help identifying populations that have the highest probability to respond to a particular treatment.

IAG’s scientific rheumatology experts will discuss the role of precision medicine and Artificial Intelligence in OA drug development. 

If you are not attending, schedule a call: imaging.experts@ia-grp.com

About OARSI

OARSI is the premier international organization for scientists and health care professionals focused on the prevention and treatment of osteoarthritis through the promotion and presentation of research, education and the worldwide dissemination of new knowledge. To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events